CAMP4 Therapeutics (CAMP) begins GLP toxicology work on CMP-SYNGAP-01 program

Rhea-AI Filing Summary

CAMP4 Therapeutics Corporation furnished an update that it has initiated GLP (good laboratory practice) toxicology studies for its program called CMP-SYNGAP-01. These studies are a standard non‑clinical step used to evaluate safety before a potential move into later development stages.

The update was shared through a press release titled “CAMP4 Therapeutics Initiates GLP Toxicology Studies for CMP-SYNGAP-01,” which is included as an exhibit to this report. The information is being provided for disclosure purposes and is not being treated as filed under the securities laws unless specifically incorporated by reference elsewhere.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

0001736730false00017367302025-10-012025-10-01

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 1, 2025

CAMP4 THERAPEUTICS CORPORATION

(Exact name of registrant as specified in its charter)

Delaware

001-42365

81-1152476

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer Identification No.)

One Kendall Square Building 1400 West, 3rd Floor Cambridge, MA

02139

(Address of principal executive offices)

(Zip Code)

(Registrant’s telephone number, including area code): (617) 651-8867

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.0001 per share

CAMP

The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 7.01. Regulation FD Disclosure.

On October 1, 2025, CAMP4 Therapeutics Corporation (the “Company”) issued a press releases titled “CAMP4 Therapeutics Initiates GLP Toxicology Studies for CMP-SYNGAP-01,” a copy of which is furnished as Exhibit 99.1 hereto.

The information responsive to Item 7.01 of this Form 8-K and Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.						Description
99.1						Press release issued by CAMP4 Therapeutics Corporation on October 1, 2025.
104						Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			CAMP4 THERAPEUTICS CORPORATION
			By:			/s/ Kelly Gold
						Name: Kelly Gold
						Title:   Chief Financial Officer

Date: October 1, 2025

FAQ

What did CAMP (CAMP4 Therapeutics) disclose in this 8-K?

CAMP4 Therapeutics disclosed that it has initiated GLP toxicology studies for its program CMP-SYNGAP-01, as described in a furnished press release.

What is CMP-SYNGAP-01 in CAMP4 Therapeutics' pipeline?

CMP-SYNGAP-01 is the name of a CAMP4 Therapeutics program referenced in the press release; the company reports that GLP toxicology studies for this program have begun.

How was the CMP-SYNGAP-01 update communicated by CAMP4 Therapeutics (CAMP)?

The company issued a press release titled “CAMP4 Therapeutics Initiates GLP Toxicology Studies for CMP-SYNGAP-01”, which is furnished as Exhibit 99.1.

Is the CMP-SYNGAP-01 information considered filed for liability purposes?

The company states that the information under Item 7.01 and Exhibit 99.1 is furnished, not filed, and is not subject to Section 18 liabilities except if later specifically incorporated by reference.

Which exhibit contains the CAMP4 Therapeutics CMP-SYNGAP-01 press release?

Exhibit 99.1 contains the press release about initiating GLP toxicology studies for CMP-SYNGAP-01.

Who signed the CAMP (CAMP4 Therapeutics) 8-K report?

The report was signed on behalf of CAMP4 Therapeutics Corporation by Kelly Gold, its Chief Financial Officer.